ClinicalTrials.gg

Program

RO7806881

A development code.

Its studies are led by Hoffmann-La Roche.

Furthest: phase 1, since Nov 26, 20251 company-led study, 1 open or runningNext primary completion: May 11, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche11 open or runningphase 1since Nov 26, 2025Nov 26, 2025May 11, 2027phase 1 · NCT07271693

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 26, 2025First study: phase 1 study in Healthy VolunteersFirst studyNCT07271693 · 128 planned · New Zealand

Ahead

  1. May 11, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07271693

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07271693Healthy Volunteers · New Zealand1RecruitingMay 11, 2027128

How it is read

Names in the registry

  • “RO7806881”, 1 entry

Codes read as this program: RO7806881.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
    RO7806881 (Hoffmann-La Roche): development program | ClinicalTrials.gg